Leadership Review


Vermillion, Inc.

in
Vermillion, Inc. announced the appointment of John F. Hamilton to its board of directors.

ev3 Inc

in
ev3 Inc appointed Robert J. Palmisano as President, Chief Executive Officer and Director, effective immediately. Dan Levangie, a current ev3 director and the Lead Independent Director, has been appointed non-executive Chairman of the Board of Directors.

MedCath Corp

in
MedCath Corp. announced that Pamela G. Bailey and Edward R. Casas have been appointed to its Board of Directors. Ms.

Roche Holding AG

in
Roche Holding AG announced resignation of Franz Humer as chief executive. Humer, 61, led Roche's drive to develop a leading line of cancer drugs. As he handed over his duties to Severin Schwan, formerly head of Roche's diagnostics unit, the company has the richest valuation of any large European pharmaceutical business and the most promising portfolio of new drugs.
 

La Jolla Pharmaceutical Co.

in
La Jolla Pharmaceutical Co. confirmed promotion of Luke Seikkula to the position of Vice President, Manufacturing, reporting to Deirdre Gillespie, President & CEO. The effective date of this promotion was February 5, 2007.
 

Nxstage Medical Inc.

in
Nxstage Medical Inc. announced that Emil Paganini, MD, formerly Section Head of Dialysis and Extracorporeal Therapy with the Cleveland Clinic Foundation, has joined the company as Critical Care Medical Advisor. Dr.

Keryx Biopharmaceuticals Inc.

in
Keryx Biopharmaceuticals Inc. announced that as a result of cost-cutting initiatives resulting from the recent clinical failure of Sulonex, the company's Chief Accounting Officer, Mark Stier will resign effective June 30, 2008.
 

Ambrx Inc

in
Ambrx Inc. announced the appointment of Douglas W. Axelrod, M.D., Ph.D., as Senior Vice President for Clinical Research and Development. Axelrod joins Ambrx after a productive career spanning nearly two decades at Procter & Gamble Pharmaceuticals.

Synvista Therapeutics, Inc

in

On March 25, 2008, the Audit Committee of the Board of Directors of Synvista Therapeutics, Inc. named Wendy A. Milici, age 36, as the Company's principal financial officer. Ms.

DaVita

in
DaVita’s chief medical officer Charles McAllister, MD, retired April 1, according to the dialysis provider. McAllister became DaVita’s CMO in 2000 and stepped down in July 2007. He has since served as CMO emeritus in the Office of the CMO. More.
 
12345678next ›last »
Syndicate content